Daptomycin
important information for the patient.
Keep this leaflet, you may need to read it again.
In case of any doubts, consult a doctor or nurse.
This medicine has been prescribed to a specific person. Do not pass it on to others. The medicine may harm another person, even if the symptoms of their illness are the same.
If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or nurse. See section 4.
The active substance of Daptomycin Reddy powder for solution for injection or infusion is daptomycin. Daptomycin is an antibacterial medicine that can stop the growth of certain bacteria. Daptomycin Reddy is used in adults and children and adolescents (from 1 to 17 years old) to treat skin and soft tissue infections. Daptomycin Reddy is also used to treat blood infections related to skin infections.
Daptomycin Reddy is also used in adults to treat infections of the tissues lining the heart from the inside (including heart valves), caused by a bacterium called Staphylococcus aureus.Daptomycin Reddy is also used to treat blood infections caused by the same bacterium that causes heart infections.
Depending on the type of infection, during treatment with Daptomycin Reddy, the doctor may also prescribe other antibacterial medicines.
Before starting treatment with Daptomycin Reddy, the patient should consult their doctor or nurse:
in patients receiving Daptomycin Reddy, muscle pain or muscle sensitivity, or muscle weakness may occasionally occur. In such cases, the patient should inform their doctor. The doctor will decide whether to continue treatment with Daptomycin Reddy. The mentioned symptoms usually disappear within a few days after stopping treatment with Daptomycin Reddy.
in case of severe obesity. Daptomycin concentrations in the blood may be higher compared to concentrations in people with average body weight, and in such cases, if side effects occur, careful monitoring of the patient is necessary.
If any of the above points apply to the patient, they should inform their doctor or nurse before starting treatment with Daptomycin Reddy.
The patient should immediately inform their doctor or nurse if they experience any of the following symptoms:
severe, acute allergic reactions have been observed in patients treated with almost all antibacterial medicines, including daptomycin. Symptoms may include: wheezing, difficulty breathing, swelling of the face, neck, and throat, rash, and hives or fever.
serious skin disorders have been reported during treatment with daptomycin. Symptoms that may occur in this case include:
the onset or worsening of fever,
red, raised, or fluid-filled bumps on the skin, which may start under the arms or on the chest or in the groin and may spread to a large part of the body,
blisters or ulcers in the mouth or on the genitals.
serious kidney problems have been reported during treatment with daptomycin. Symptoms may include: fever and rash.
tingling or numbness of the hands or feet, loss of sensation, or difficulty moving. If these symptoms occur, the patient should inform their doctor, who will decide whether to discontinue or continue treatment.
diarrhea, especially if it contains blood or mucus, or if the diarrhea becomes acute or persistent.
the onset or worsening of fever, cough, or difficulty breathing. These may be symptoms of a rare but serious lung disorder called eosinophilic pneumonia.
The doctor will examine the patient's lungs and decide whether to continue or discontinue treatment with Daptomycin Reddy.
Daptomycin Reddy may affect the results of laboratory tests that determine blood clotting. Laboratory test results may indicate poor blood clotting when, in fact, blood clotting is normal. It is therefore important for the doctor to consider that the patient is taking Daptomycin Reddy. The patient should inform their doctor about taking Daptomycin Reddy.
To monitor muscle condition, the doctor may order blood tests before starting treatment, as well as multiple times during treatment with Daptomycin Reddy.
Daptomycin Reddy should not be given to children under one year of age, as animal studies have shown that this age group may experience severe side effects.
Patients over 65 years old, if they do not have kidney disease, can be given the same dose as recommended for adults.
The patient should tell their doctor or nurse about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
It is especially important to inform the doctor about:
medicines called statins or fibrates (which lower cholesterol levels) or cyclosporine (a medicine used in transplantology to prevent rejection of the transplant or in other conditions, such as rheumatoid arthritis or atopic dermatitis). Taking any of these (or other muscle-acting) medicines during treatment with Daptomycin Reddy may increase the risk of muscle side effects.
The doctor will decide whether to discontinue Daptomycin Reddy or temporarily stop taking other medicines.
painkillers called non-steroidal anti-inflammatory drugs (NSAIDs) or COX-2 inhibitors (e.g., celecoxib). They may affect the action of Daptomycin Reddy on the kidneys.
oral anticoagulants (e.g., warfarin), which prevent blood clotting. The doctor may need to monitor blood clotting time.
Daptomycin Reddy is not usually given to pregnant women. If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before taking this medicine.
Daptomycin Reddy should not be used during breastfeeding, as it may pass into breast milk and harm the baby.
There are no known cases of Daptomycin Reddy affecting the ability to drive or operate machinery.
The medicine contains less than 1 mmol (23 mg) of sodium per dose, which means the medicine is considered "sodium-free".
Daptomycin Reddy is usually administered by a doctor or nurse.
Adults (18 years and older)
The dose of the medicine depends on body weight and the type of infection being treated. The usual dose of the medicine for adults is:
In adult patients, the medicine is administered directly into the bloodstream (intravenously) as a 30-minute infusion or a 2-minute injection. The same dose is recommended for people over 65 years old, if they do not have kidney disease.
In patients with kidney function disorders, Daptomycin Reddy may be administered less frequently, e.g., every other day. In patients undergoing dialysis, if the next dose of Daptomycin Reddy is due on the day of dialysis, Daptomycin Reddy is usually administered after dialysis.
Children and adolescents (from 1 to 17 years old)
The dose for children and adolescents (from 1 to 17 years old) will depend on the patient's age and the type of infection being treated. The dose is administered directly into the bloodstream (intravenously) as an infusion lasting approximately 30-60 minutes.
Treatment of skin infections usually lasts from 1 to 2 weeks. In blood or heart infections, as well as skin infections, the duration of treatment will be decided by the doctor.
Detailed instructions for the use and preparation of the medicine are provided at the end of this leaflet.
If the patient has any further questions about the use of this medicine, they should consult their doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The most serious side effects are described below:
Severe side effects with unknown frequency(frequency cannot be determined from available data)
The most commonly reported side effects are described below:
Common side effects(may occur in less than 1 in 10 people)
Other side effects that may occur after taking Daptomycin Reddy are described below:
Uncommon side effects(may occur in less than 1 in 100 people)
Rare side effects(may occur in less than 1 in 1,000 people)
Frequency not known(frequency cannot be determined from available data)
Pseudomembranous colitis associated with antibacterial action, including pseudomembranous colitis [severe or persistent diarrhea with blood and/or mucus, associated with abdominal pain or fever], easy bruising, bleeding from the gums or nose.
If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and label after EXP.
The expiry date refers to the last day of the month stated.
Store in a refrigerator (2°C-8°C).
After reconstitution: The chemical and physical stability of the reconstituted solution in the vial has been demonstrated for 12 hours at 25°C and up to 48 hours at 2°C-8°C.
The chemical and physical stability of the diluted solution in infusion bags has been established for 12 hours at 25°C or 24 hours at 2°C-8°C.
In the case of a 30-minute intravenous infusion, the total storage time (of the reconstituted solution in the vial and the diluted solution in the infusion bag) at 25°C should not exceed 12 hours (or 24 hours at 2°C-8°C).
In the case of a 2-minute intravenous injection, the storage time of the reconstituted solution in the vial at 25°C should not exceed 12 hours (or 48 hours at 2°C-8°C).
However, from a microbiological point of view, the prepared product should be used immediately.
The product does not contain a preservative or bacteriostatic agent. If the product is not used immediately, the user is responsible for the storage time, and it should not exceed 24 hours at 2°C-8°C, unless reconstitution/dilution was performed under controlled and validated aseptic conditions.
Do not use this medicine if visible signs of deterioration are observed, i.e., the presence of solid particles.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substance is daptomycin.
One vial of powder contains 350 mg of daptomycin.
One ml of solution after reconstitution of the powder in 7 ml of 9 mg/ml (0.9%) sodium chloride injection contains 50 mg of daptomycin.
One vial of powder contains 500 mg of daptomycin.
One ml of solution after reconstitution of the powder in 10 ml of 9 mg/ml (0.9%) sodium chloride injection contains 50 mg of daptomycin.
The other ingredient is sodium hydroxide to adjust the pH.
Daptomycin Reddy powder for solution for injection/infusion is a light yellow to light brown disc or powder in glass vials. Before administration, the powder should be mixed with the solvent to form a solution.
Daptomycin Reddy is available in packs containing 1 vial in a cardboard box.
Not all pack sizes may be marketed.
Reddy Holding GmbH
Kobelweg 95
86156 Augsburg
Germany
Tel.: +49 821 74881 0
betapharm Arzneimittel GmbH
Kobelweg 95
86156 Augsburg
Germany
SC Rual Laboratories SRL
Splaiul Unirii nr 313, Building H, 1 floor, sector 3
030138 Bucharest
Romania
Germany | Daptomycin beta 350/500 mg powder for solution for injection/infusion |
Czech Republic: | Daptomycin Reddy |
Ireland | Daptomycin 350/500 mg powder for solution for injection/infusion |
Netherlands: | Daptomycine Reddy 350/500 mg powder for solution for injection/infusion |
Poland | Daptomycin Reddy |
Portugal | Daptomycin Reddy 350/500 mg powder for solution for injection/infusion |
Romania | Daptomicină Dr. Reddy’s 350/500 mg powder for solution for injection/infusion |
Slovakia | Daptomycin Reddy 350/500 mg powder for solution for injection/infusion |
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.